Categories: News

NYSE Content advisory: Pre-Market update + Trump tariffs to resume Aug. 1

NEW YORK, July 7, 2025 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins. 

- Advertisement -

Kristen Scholer delivers the pre-market update on July 7th

- Advertisement -
  • S&P 500 begins week coming off a record close
  • White House says reciprocal tariffs go into effect August 1
  • President Trump’s tax and spending bill officially signed into law on July 4

Opening Bell
Kode with Klossy celebrates its 10-year anniversary

- Advertisement -

Closing Bell
WisdomTree (NYSE: WT) celebrates the 10th anniversary of its Yield Enhanced U.S. Aggregate Bond ETF (NYSE Arca: AGGY)

- Advertisement -

Click here to download the NYSE TV App

- Advertisement -

Video – https://mma.prnewswire.com/media/2725584/NYSE_July_7_Market_Update.mp4
Logo – https://mma.prnewswire.com/media/2581322/New_York_Stock_Exchange_Logo.jpg 

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/nyse-content-advisory-pre-market-update–trump-tariffs-to-resume-aug-1-302498805.html

- Advertisement -

Recent Posts

Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

February 06, 2026 16:01 ET  | Source: Ocular Therapeutix, Inc. BEDFORD, Mass., Feb. 06, 2026…

6 hours ago

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 06, 2026 16:01 ET  | Source: NewAmsterdam Pharma N.V. NAARDEN, The Netherlands and MIAMI,…

6 hours ago

Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery

New facility will enable end‑to‑end discovery across key disease areas and technology platforms, joining existing…

6 hours ago

The Ministry of Finance and the International Monetary Fund to launch tomorrow the second edition of the AlUla Conference for Emerging Market Economies

AlUla, Saudi Arabia, Feb. 7, 2026 /PRNewswire/ -- The second edition of the AlUla Conference…

6 hours ago

Roches fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)

Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint…

6 hours ago

Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement

February 06, 2026 17:17 ET  | Source: Lexicon Pharmaceuticals, Inc. THE WOODLANDS, Texas, Feb. 06,…

6 hours ago